The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir

Background Currently available antiretroviral 2-drug regimen (2DR) fixed dose combinations may not be suitable for specific situations including the presence of resistance associated mutations (RAM) or drug − drug interactions (DDI). The data on the use of the non-nucleoside reverse transcriptase in...

Full description

Saved in:
Bibliographic Details
Published in:Infection 2023-12, Vol.51 (6), p.1823-1829
Main Authors: Sammet, Stefanie, Touzeau-Römer, Veronique, Wolf, Eva, Schenk-Westkamp, Pia, Romano, Birgit, Gersbacher, Elke, Kastenbauer, Ulrich, Boesecke, Christoph, Rockstroh, Jürgen, Scholten, Stefan, Schneeweiss, Stephan, Roider, Julia, Seybold, Ulrich
Format: Article
Language:English
Subjects:
Antiretroviral agents
Antiretroviral drugs
Brief Report
Cardiovascular diseases
CD4 antigen
Drug interaction
Family Medicine
General Practice
Health risks
HIV
Human immunodeficiency virus
Infectious Diseases
Inhibitors
Integrase
Internal Medicine
Medicine
Medicine & Public Health
Non-nucleoside reverse transcriptase inhibitors
Observational studies
Risk management
RNA-directed DNA polymerase
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Currently available antiretroviral 2-drug regimen (2DR) fixed dose combinations may not be suitable for specific situations including the presence of resistance associated mutations (RAM) or drug − drug interactions (DDI). The data on the use of the non-nucleoside reverse transcriptase inhibitor doravirine (DOR) and the integrase inhibitor dolutegravir (DTG) as an alternative 2DR remain scarce. Methods People living with HIV with DOR + DTG as a 2DR are being followed in a prospective observational study. Results This analysis describes 85 participants with a median age of 57 years. Median CD4-nadir was 173/µl and a majority (66%) had a history of HIV-associated or AIDS-defining conditions. Antiretroviral history was mostly extensive, and documentation of RAM was frequent. The main reasons for choosing DOR + DTG were DDI (29%), tolerability (25%), and cardiovascular risk reduction (21%). Plasma viral load at switch was 
ISSN:0300-8126
1439-0973
DOI:10.1007/s15010-023-02075-y